Historical Valuation
Molecular Partners AG (MOLN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.71. The fair price of Molecular Partners AG (MOLN) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：4.10
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Molecular Partners AG (MOLN) has a current Price-to-Book (P/B) ratio of 1.31. Compared to its 3-year average P/B ratio of 0.93 , the current P/B ratio is approximately 40.43% higher. Relative to its 5-year average P/B ratio of 2.10, the current P/B ratio is about -37.72% higher. Molecular Partners AG (MOLN) has a Forward Free Cash Flow (FCF) yield of approximately -42.66%. Compared to its 3-year average FCF yield of -35.34%, the current FCF yield is approximately 20.74% lower. Relative to its 5-year average FCF yield of -15.64% , the current FCF yield is about 172.76% lower.
P/B
Median3y
0.93
Median5y
2.10
FCF Yield
Median3y
-35.34
Median5y
-15.64
Competitors Valuation Multiple
AI Analysis for MOLN
The average P/S ratio for MOLN competitors is 0.00, providing a benchmark for relative valuation. Molecular Partners AG Corp (MOLN.O) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for MOLN
1Y
3Y
5Y
Market capitalization of MOLN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MOLN in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MOLN currently overvalued or undervalued?
Molecular Partners AG (MOLN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.71. The fair price of Molecular Partners AG (MOLN) is between to according to relative valuation methord.
What is Molecular Partners AG (MOLN) fair value?
MOLN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Molecular Partners AG (MOLN) is between to according to relative valuation methord.
How does MOLN's valuation metrics compare to the industry average?
The average P/S ratio for MOLN's competitors is 0.00, providing a benchmark for relative valuation. Molecular Partners AG Corp (MOLN) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
What is the current P/B ratio for Molecular Partners AG (MOLN) as of Jan 10 2026?
As of Jan 10 2026, Molecular Partners AG (MOLN) has a P/B ratio of 1.31. This indicates that the market values MOLN at 1.31 times its book value.
What is the current FCF Yield for Molecular Partners AG (MOLN) as of Jan 10 2026?
As of Jan 10 2026, Molecular Partners AG (MOLN) has a FCF Yield of -42.66%. This means that for every dollar of Molecular Partners AG’s market capitalization, the company generates -42.66 cents in free cash flow.
What is the current Forward P/E ratio for Molecular Partners AG (MOLN) as of Jan 10 2026?
As of Jan 10 2026, Molecular Partners AG (MOLN) has a Forward P/E ratio of -3.11. This means the market is willing to pay $-3.11 for every dollar of Molecular Partners AG’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Molecular Partners AG (MOLN) as of Jan 10 2026?
As of Jan 10 2026, Molecular Partners AG (MOLN) has a Forward P/S ratio of 0.00. This means the market is valuing MOLN at $0.00 for every dollar of expected revenue over the next 12 months.